SRFF Named-Partner, Marc J. Ross, Leads Transaction Whose Proceeds Will fund Development of Medications for the Treatment of Fibromyalgia and Post-Traumatic Stress Disorder
NEW YORK CITY – February 12, 2014Sichenzia Ross Friedman Ference LLP (SRFF), a leading corporate securities law firm headquartered in New York City, announces it represented Tonix Pharmaceuticals Holding Corp. (TNXP) in the closing of its confidentially marketed public offering, resulting in aggregate gross proceeds of approximately $43.5 million. The shelf takedown, which closed January 29, 2014, was led by SRFF named partner Marc J. Ross.
The SRFF team, which in addition to Ross as lead counsel included firm partner James M. Turner, advised Tonix in the underwritten public offering of 2,898,550 shares of the common stock at a price of $15.00 per share. Roth Capital Partners acted as the sole book-running manager for the offering and National Securities Corporation, a wholly owned subsidiary of National Holdings, Inc. (NHLD), acted as co-manager. Tonix granted the underwriters a 45-day option to acquire an additional 434,782 shares to cover overallotments in connection with the offering.
Tonix Pharmaceuticals develops prescription medications for disorders of the central nervous system, targeting conditions characterized by significant unmet medical needs, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. Tonix expects to use the net proceeds of the offering to support the continued development of TNX-102 SL for the treatment of fibromyalgia, to initiate clinical trials of TNX-102 SL for the treatment of post-traumatic stress disorder, and to initiate clinical trials of TNX-201 for tension-type headache.
Avista Capital Partners
Last modified: 2013-12-16T13:14:39Z
Media Contact:
pr@srf.law
(212) 930-9700
[starbox id=1]
